← Back to Search

Tyrosine Kinase Inhibitor

Nivolumab + Cabozantinib for Kidney Cancer

Phase 2
Waitlist Available
Led By Chung-Han Lee, MD, PhD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Availability of a representative formalin fixed, paraffin embedded tumor specimen or fresh frozen tissue specimen that enables the definitive diagnosis of RCC, accompanied by an associated pathology report. Specimens can be collected by surgical resection or biopsy of the primary tumor or biopsy or resection of a metastatic lesion
Pathologic or histologically confirmed unresectable advanced or metastatic nccRCC
Must not have
Serious non-healing wound/ulcer/bone fracture
Corrected QT interval calculated by the Frederica formula (QTcF) > 500 ms per elFectrocardiogram (ECG) within 28 days before first dose of study treatment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a combination of two drugs, nivolumab and cabozantinib, in people with metastatic kidney cancer. Nivolumab helps the immune system attack cancer cells, while cabozantinib blocks signals that help cancer grow. The goal is to see if this combination works better than other treatments.

Who is the study for?
This trial is for adults (18+) with advanced or metastatic non-clear cell renal cell carcinoma who've had 0 or 1 prior treatments. They must be able to understand the study, consent to it, and agree to use contraception if fertile. Excluded are those on certain medications, with severe allergies, HIV/hepatitis B/C infections, uncontrolled conditions like hypertension or thyroid issues, recent major surgery, brain/spinal cancer history or significant cardiovascular disease.
What is being tested?
The study tests a combination of two drugs: Nivolumab (Opdivo®) and Cabozantinib (Cabometyx®), in patients with metastatic kidney cancer. It aims to assess the benefits and adverse effects compared to current standard treatments.
What are the potential side effects?
Potential side effects include immune-related reactions such as inflammation in organs; high blood pressure; fatigue; liver issues; digestive disturbances like nausea and diarrhea; increased protein in urine; mouth sores; hand-foot syndrome.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can provide a tissue sample from my cancer for testing.
Select...
My kidney cancer cannot be removed by surgery and has spread.
Select...
I am mostly able to care for myself.
Select...
I am 18 years old or older.
Select...
I have had one or no previous systemic treatments for my condition.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a serious wound, ulcer, or bone fracture that is not healing.
Select...
My heart's electrical activity (QTcF) is not over 500 ms.
Select...
I have lung lesions or disease in my airways.
Select...
I have been treated with cabozantinib for a type of kidney cancer that is not clear cell.
Select...
I need IV fluids, nutrition, or tube feeding due to stomach or intestine problems.
Select...
My tumor is growing into or around major blood vessels.
Select...
I have previously been treated with immunotherapy.
Select...
I frequently need procedures to remove excess fluid from my chest or abdomen.
Select...
I have a history of HIV infection.
Select...
I have a serious heart condition.
Select...
My high blood pressure is not under control.
Select...
I have high calcium levels that need ongoing treatment.
Select...
I cannot swallow pills or capsules.
Select...
I do not have cancer in my brain, spinal cord, or its coverings.
Select...
I am currently taking blood thinners.
Select...
I have symptoms of underactive thyroid that aren't treated.
Select...
I have an active or chronic hepatitis B or C infection.
Select...
My liver is not working well.
Select...
I have not had a stroke or mini-stroke in the last 6 months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
objective response rate

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: Cohort 4: Unclassified, papillary, and HL RCCExperimental Treatment2 Interventions
Cohort 4 is an expansion of Cohorts 1+3, which will accure an additional 40 patients
Group II: Cohort 3: Unclassified, papillary, and HL RCCExperimental Treatment2 Interventions
Cohort 3 is designed as an expansion cohort of Cohort 1 with 20 additional patients to obtain a more precise estimate of the ORR and clinical outcomes
Group III: Cohort 2: Chromophobe RCCExperimental Treatment2 Interventions
Cohort 2 is designed as a Simon's optimal two-stage design with a total possible sample size of 17. This design discriminates between ORR rates of 5 and 25%.
Group IV: Cohort 1: Unclassified, papillary, and HL RCCExperimental Treatment2 Interventions
Cohort 1 is designed as a single stage study with a total sample size of 20. This design discriminates between ORR rates of 10 and 35%.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
nivolumab
2016
Completed Phase 3
~5250
cabozantinib
2011
Completed Phase 3
~1240

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Renal Cell Carcinoma (RCC) include immune checkpoint inhibitors and tyrosine kinase inhibitors. Immune checkpoint inhibitors, such as Nivolumab, work by blocking proteins like PD-1 on immune cells, thereby enhancing the body's immune response against cancer cells. Tyrosine kinase inhibitors, such as Cabozantinib, target specific enzymes (tyrosine kinases) involved in the growth and spread of cancer cells, effectively inhibiting tumor growth and angiogenesis. These treatments are crucial for RCC patients as they offer targeted approaches to slow disease progression and improve survival rates, especially in advanced or metastatic cases.
Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis.Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,973 Previous Clinical Trials
597,678 Total Patients Enrolled
Chung-Han Lee, MD, PhDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
Darren Feldman, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
8 Previous Clinical Trials
1,740 Total Patients Enrolled

Media Library

Cabozantinib (Tyrosine Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03635892 — Phase 2
Renal Cell Carcinoma Research Study Groups: Cohort 2: Chromophobe RCC, Cohort 4: Unclassified, papillary, and HL RCC, Cohort 1: Unclassified, papillary, and HL RCC, Cohort 3: Unclassified, papillary, and HL RCC
Renal Cell Carcinoma Clinical Trial 2023: Cabozantinib Highlights & Side Effects. Trial Name: NCT03635892 — Phase 2
Cabozantinib (Tyrosine Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03635892 — Phase 2
~5 spots leftby Aug 2025